Valneva’s next-gen Zika vaccine shows strong safety and immune response in phase I trial
VLA1601 is a purified and inactivated vaccine specifically designed to protect against the Zika virus
VLA1601 is a purified and inactivated vaccine specifically designed to protect against the Zika virus
RedHill has obtained a court-approved asset attachment in South Korea to prevent Kukbo from transferring or disposing of assets ahead of enforcement of the judgment
The study demonstrated strong clinical outcomes, with 94.8 per cent of subjects remaining free from major target limb amputation at one year
The expanded approval allows Kerendia to be prescribed to heart failure patients with a LVEF of 40% or more
From material selection to cooling tower management, every small decision affects long-term equipment reliability
Building a transparent, data-driven supply chain and self-reliant API ecosystem remains critical to reducing import dependence
This is the first industry-academia collaboration in the country, initiated through the CSR route, for advancing research in the areas of immuno-therapeutics and regenerative medicines
The company has posted net profit of Rs. 283 crore for the 6 months period ended September 30, 2025
Subscribe To Our Newsletter & Stay Updated